In the same FH patients examined in this study [111], the authors have already shown a decrease in small dense LDL, known to be more susceptible to oxidative modification and widely recognized as predictors of atherosclerosis, coronary heart disease, and stroke, suggesting an association between their reduction and changes in oxidation markers and endothelial function in FH patients receiving PCSK-9 inhibitors [112]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.